Review authors judgments about each risk of bias item presented as percentages across all included studies. by Xiaodong Jia (783460)

Subjects:

Inclusion of literature flowchart. by Xiaodong Jia (783460)

Subjects:

Effect of biologics on low density lipoprotein (LDL). by Xiaodong Jia (783460)

Subjects:

Effect of biological agents on total cholesterol outcomes forest results. by Xiaodong Jia (783460)

Subjects:

Sensitivity analysis. by Xiaodong Jia (783460)

Subjects:

Effect of biologics on triglyceride outcomes of RA forest results. by Xiaodong Jia (783460)

Subjects:

Forest plot of the effect of biologic therapy versus conventional therapy on low-density lipoprotein levels stratified by different drug treatments. by Xiaodong Jia (783460)

Subjects:

Forest plot of the effect of biologic therapy versus conventional therapy on total cholesterol levels stratified by different drug treatments. by Xiaodong Jia (783460)

Subjects:

Basic characteristics of research. by Xiaodong Jia (783460)

Subjects:

Forest plot of the effect of biologic therapy versus conventional therapy on triglyceride levels stratified by treatment duration. by Xiaodong Jia (783460)

Subjects:

Forest plot of the effect of biologic therapy versus conventional therapy on triglyceride levels stratified by different drug treatments. by Xiaodong Jia (783460)

Subjects:

Shows the 5′ region and the exons of the <i>C3</i> gene in the vertical line and the three new SNPs that we found by sequencing. by Yonghui Wang (287491)

Summary of the effect of MPDD on ART and TIBL across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “... by Mobina Faqani (22783963)

IC₅₀ of indole alkaloid against lipase [23]. by Atikarn Janthongkaw (17020498)

Recombination of Autodissociated Water Ions in a Nanoscale Pure Water Droplet by Soonho Kwon (1402972)

Subjects:

Univariable and multivariable analyses (age-adjusted), concerning a selection of medicaments p < 0.1 and n ≥ 10. by P.G.J. ter Horst (21743830)

Advancing the science of NOWS research. by Sarah E. Maylott (14560785)

“…Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. We propose noninvasive clinical indicators of NOWS, including newborn neurobehavior, autonomic biomarkers, prenatal substance exposures, and socioeconomic environments. …”

Protocol measures. by Sarah E. Maylott (14560785)

“…Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. We propose noninvasive clinical indicators of NOWS, including newborn neurobehavior, autonomic biomarkers, prenatal substance exposures, and socioeconomic environments. …”

Cry variables. by Sarah E. Maylott (14560785)

“…Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. We propose noninvasive clinical indicators of NOWS, including newborn neurobehavior, autonomic biomarkers, prenatal substance exposures, and socioeconomic environments. …”

Phosphorylation as an Effective Tool to Improve Stability and Reduce Toxicity of Antimicrobial Peptides by Zufang Ba (11036420)

“…Phosphorylation can reduce toxicity and improve the stability of AMPs. Based on these, we designed a series of peptides and their corresponding phosphorylated forms. …”